tempting to think that it might not be that difficult to
time it became clear that cancer, a condition which had been conveniently used to exemplify to generations of The effort to harness advances in basic biology for medistudents the dichotomy between inherited and acquired cal purposes, and more specifically in order to design disorders, is itself a genetic disorder of somatic cells: new forms of treatment, has been a recurrent theme and therefore, why not try to cure cancer by correcting its a natural trend in history. It is hardly surprising that the genetic abnormalities, or perhaps by producing locally explosive development of molecular biology has led to biological anticancer agents. This issue is not entirely septhe notion that we should try to use genes to treat arate from one raised in the previous section, because the human diseases.
treatment of cancer may be perceived by industry as offering a much wider and wealthier market than the Biology and technology treatment of some of the inherited disorders with the In order to tackle severe diabetes it was necessary to highest prevalence in human populations. know on the one hand that a specific substance produced Of course the rationale for genetic correction of an in the pancreatic islets controls the blood sugar; on the inherited disorder versus genetic correction of cancer is other hand, one needed the technical expertise of protein fundamentally different. In the former case we are often chemistry to purify insulin. Bringing scientific advances dealing with a recessive condition due to a loss of funcfrom the test tube to the bedside has always required tion; thus, even a very partial correction could have a biology plus technology. Again, gene therapy is no major clinical impact (for instance, production of factor exception: on the one hand we need to understand how VIII to yield a plasma level as low as 5% of normal would gene correction operates in appropriate cells; on the other convert a severe hemophiliac to a mild hemophiliac). In hand, we need efficient technology for gene transfer. The the latter case we are dealing with a condition where one development of gene therapy takes place at a time when or more somatic mutations have -by definition -prothe relationship between research in academic instiduced in somatic cells a phenotype that dominates the tutions and developments in industry is rather different scene: therefore, any direct gene correction approach that from what it used to be. Traditionally, new drugs have falls short of correcting 100% of the cells is not likely to been discovered by industry and biological processes have anything but a transient effect. Here we have a good have been discovered by academic research; but if a example of how the difference is in the biology, but the 'drug' is a gene that must be packaged in a vector that technology is paramount, because dramatic improvement must be delivered to certain cells manipulated in vitro for in gene transfer efficiency would be needed to make the some time and then introduced into a patient, the separlatter proposition realistic. ation between the drug and the biological process For a physician it is a humbling admission to make becomes rather blurred. For these reasons, it has been that at the moment, in the case of solid tumors the hope regarded as axiomatic that marrying academia with of cure lies in surgery, not in medicine. Ehrlich's concept industry would benefit gene therapy, although this conof the magic bullet, which worked so well for bacteria, cept has not been tested, much less proven, in any conhas not worked as well for neoplastic cells, mainly trolled trial.
because these are so similar to normal cells. In fact, the history of oncology has abundantly validated a variation on that theme: there is no single 'cure for cancer', but Traditional inherited diseases versus cancer The notion that serious disorders could be the consesound work on the mechanism of action of drugs and radiation, intelligent combinations of these agents, and quence of minute abnormalities in the genome has been innate to classical genetics; yet, it was not a small relief painstaking design and execution of clinical trials can bring about substantial results in many individual types when, first through protein analysis, and then through DNA analysis 1 it was conclusively proven that it was of cancer; rather spectacular, for instance, in the case of certain leukemias, certain lymphomas and germ cell actually true in the prototype case of sickle cell anemia, and in scores of other cases since. If a single base pair tumors. 2 Once again, it is probably wise to think of cancer gene therapy along the same lines. At the moment, it change could be the culprit, it became immediately seems hard to reverse literally the malignant phenotype:
result from the HSVtk expression being insufficient, or only transient, or both. Dual-promoter vectors are often either because we don't know exactly what has gone awry (inadequate biology), or because we cannot do it subject to transcriptional interference. 11, 12 This could lead to dissociation between expression of the marker gene with enough efficiency (inadequate technology). In the meantime, however, we can apply our ingenuity to using (under the transcriptional control of the 5′ long terminal repeat), and the suicide gene (under the control of a gene transfer in conjunction with other agents and in a variety of ways in order to control a malignant process.
downstream internal promoter 9 ), despite the integration of an intact copy of the vector. Thus, lymphocytes cannot be made safe by just achieving a high level of purifiLateral thinking: the manufacture of safe T lymphocytes and the renaissance of adoptive cell therapies cation; in fact, it would be misleading to rely only on purification until co-expression is rigorously established For over 30 years, the infusion of T lymphocytes into syngeneic or allogeneic recipients has been used by immunoand maintained. One of us has recently demonstrated, also in human T lymphocytes, that the problem of tranlogists to probe the function of effector and regulatory lymphocytes in vivo.
3 This procedure, originally termed scriptional interference and unreliable gene co-expression can be solved with optimized single promoter dicistronic adoptive transfer of immunity to distinguish it from the passive transfer of serum or antibodies, is still used in vectors. 13 Fortunately, we know from dose-response studies in allogeneic BMT recipients that small doses of countless animal models to either induce or treat various diseases, including cancer. Allogeneic bone marrow donor T cells are not sufficient to cause GVHD, 14 suggesting that there may be a tolerable low level of infusion of transplantation (BMT) represents a special setting in which the administration of T cells was at first an inadnontransduced T lymphocytes. vertent adoptive transfer associated with the infusion of bone marrow. The donor T cells present in the graft can Policies, politics and publicity Gene therapy was regarded with great respect throughprovide therapeutic benefits, such as antileukemic effects and enhanced donor marrow engraftment, but also lifeout the 1980s, and hardly any article recording the cloning of a disease-related gene failed to conclude that genthreatening complications, primarily graft-versus-host disease (GVHD). 4 Of course numerous attempts have etic correction was now in the offing. A sense of urgency in producing therapeutic applications was created not been made to separate these two types of effects, but with little success. The only safe and efficient approach only by venture capitalists who were investing in biotechnology companies; but also, quite independently, by developed so far has been to narrow down the specificity of the donor T lymphocytes to a single one, ie, to generate another group animated by a far more personal, pressing and understandable vested interest, namely the patients T cell clones 5 (eg anti-CMV). However, once again we have limitations. The main biological limitation is that a themselves. Today patients may feel encouraged by hearing that there are some 140 gene therapy protocols active narrow repertoire precludes the targeting of multiple antigens: thus, one would miss the antileukemic effect.
in the USA alone. However, it is not equally widely publicized that (apart from some marking studies of great The technical limitation is the time necessary to generate the clones -racing over a few critical weeks against rapbiological interest but not having therapeutic intents) the large majority of these are 'phase I' studies, which means idly progressing disease.
An alternative approach -generating polyclonal T lymthat they are only meant to test the new treatment for its potential side-effects, not for its therapeutic efficacy. At phocytes from the donor -is highly attractive, as long as an appropriate safeguard is incorporated. A suicide gene the time of writing, we cannot boast of gene therapy having unquestionably conquered any disease. Does this (such as the herpes simplex virus thymidine kinase (HSVtk) ) that renders the transduced cells specifically mean that we miscalculated, or that we are too slow, or simply that we are too impatient (after all, it took some sensitive to a prodrug 6-8 would provide such a safeguard; when GVHD develops, administration of the pro-drug decades from the finding that pancreatectomized dogs develop diabetes to the time when the first diabetic should promptly abrogate it. In the original description of this strategy, 6 one of us placed the emphasis on: (1) patient was able to buy insulin in the pharmacy)? In 1995, Arno Motulsky and Stuart Orkin were asked by the US efficient purification of transduced lymphocytes based on the expression of a marker before their infusion; and (2) National Institutes of Health to assess the status of gene therapy. The resulting report was a critical but balanced faithful co-expression of the marker and of the suicide gene encoded by the vector, in order to ensure that virappraisal of what is real and of what is realistic, a model of objectivity, and a good shortlist of commonsense rectually all infused T cells express sufficient levels of the suicide gene in vivo.
ommendations. By the front-line workers the report was read as a warning that 'rush to press' and 'rush to the The group of Claudio Bordignon in Milan has now reported on the use of precisely this strategy in eight clinic' was not a good idea in the area of gene therapy any more than in most other scientific endeavours; and patients. Five patients did not develop GVHD; the three who did were treated with ganciclovir, which reversed therefore serious scientists and serious clinicians welcomed the report. Unfortunately, for those that like simsigns of GVHD in two of them. 9 It is impossible to extrapolate from such small numbers, but this pilot study ple dichotomies, the report could also be read as heralding an era of gene therapy scepticism, following the is important for at least three reasons. (1) From the evidence of two patients, it appears that the strategy works; era of gene therapy enthusiasm. Another factor in the backlash has probably been a flurry of premature claims this is good news for a field that is in dire need of real clinical results. (2) Not all cells always commit suicide:
and premature hopes fed by hypes, which is not just the media's, but our responsibility to curb. This is another this is probably because marker-negative cells (as well as 'pseudo-transduced' lymphocytes 10 ) are simply not elimreason why the article with real results by Bordignon's group is so important. inated. (3) An incomplete response to ganciclovir could
